Moleculin Biotech

181 articles with Moleculin Biotech

• Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

  6/16/2022

  Preliminary results of first cohort in the first-in-human Phase 1a allows Company to proceed to 16 mg/kg dose of WP1122 in second cohort toward establishing maximum tolerated dose (MTD).

• 

  Clinical Catch-Up: 3's the Charm for Pfizer-BioNTech Vaccine in Kids & More

  5/30/2022

  A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.

• Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

  5/26/2022

  Moleculin Biotech, Inc. today announced the commencement of dosing in its first-in-human Phase 1a study to evaluate the safety and pharmacokinetics (PK) of WP1122 in healthy volunteers for the treatment of COVID-19 (MB-301).

• Moleculin to Present at the H.C. Wainwright Global Investment Conference

  5/19/2022

  Moleculin to Present at the H.C. Wainwright Global Investment Conference.

• 

  Clinical Catch-Up: Updates for Achilles, Logic Bio, Roche and More

  5/16/2022

  Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio's pediatric methylmalonic acidemia study is back up and running and another look at Roche's TIGIT flop.

• Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update

  5/12/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today reported its financial results for the quarter ended March 31, 2022.

• Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

  5/10/2022

  Moleculin Biotech, Inc. today announced that it has received approval from the United Kingdom's (UK) MHRA to proceed with a first-in-human Phase 1a study to evaluate the safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19 (MB-301).

• 

  Clinical Catch-Up: Pfizer's Paxlovid Gaff, a Win for Medicago-GSK's Vaccine

  5/9/2022

  Pfizer's Paxlovid racks up a rare trial miss, Medicago and GSK publish positive data for their plant-based particle vaccine and Rhythm Pharmaceuticals touts strong potential in Bardet-Biedl Syndrome.

• Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

  5/5/2022

  Moleculin Biotech, Inc. today announced that it has received allowance from the Polish Department of Registration of Medicinal Products (URPL), as well as the requisite Ethics Committee approval, to proceed with its Phase 1/2 clinical trial in Poland of Annamycin (L-ANN).

• Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

  5/4/2022

  Moleculin Biotech, Inc. today announced that the Company has engaged Wolfram C. M. Dempke, MD, PhD, MBA, MRCP as its EU Chief Medical Officer and part-time contractor for its European clinical trials.  

• 

  Clinical Catch-Up: COVID-19 Updates from Sinovac, Moderna, Arcturus, Novavax and More

  4/25/2022

  It was yet another busy week for clinical trial news, with a range of studies for COVID-19, various cancers, fungal infections and other indications.

• Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

  4/21/2022

  Moleculin Biotech, Inc. today announced that the US Food and Drug Administration (FDA) is allowing the Company's Investigational New Drug (IND) application to study WP1066 for the treatment of recurrent malignant glioma.

• Moleculin Announces Corporate Rebranding and Launch of New Website

  4/14/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced the launch its new corporate branding and website www.moleculin.com.

• Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting

  4/8/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that preclinical data of Annamycin tested in syngeneic models of metastatic colorectal cancer established in lungs or liver was accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022.

• Moleculin Reports Full Year Financial Results and Provides Programs Update

  3/25/2022

  Moleculin Biotech, Inc. today reported its financial results for the year ended December 31, 2021.

• Moleculin to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

  3/23/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, Chairman and CEO of Moleculin Biotech, will participate at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, taking place March 28-30, 2022.

• Moleculin to Present at the Oppenheimer 32nd Annual Healthcare Conference

  3/11/2022

  Moleculin Biotech, Inc. today announced that Walter Klemp, Chairman and CEO of Moleculin Biotech, will present at the virtual Oppenheimer 32nd Annual Healthcare Conference on Thursday, March 17, 2022 at 9:20 AM ET.

• Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

  3/1/2022

  Moleculin Biotech, Inc. today announced the appointment of Joy Yan, M.D., Ph.D. to its Board of Directors.

• Moleculin Biotech, Inc. to Present at the Virtual Investor 2022 Top Picks Conference

  1/20/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Klemp, Founder, President, CEO and Chairman, will participate in the Virtual Investor 2022 Top Picks Conference.

• Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

  1/18/2022

  Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today reported that it has received an updated independent safety review of certain preliminary data for the first 30 patients in its three Phase 1 clinical trials with Annamycin targeting relapsed or refractory acute myeloid leukemia (AML) and the metastases of soft tissue sarcoma to the lungs (STS Lung).